Mipsagargin

Drug Profile

Mipsagargin

Alternative Names: G-202; Thapsigargin prodrug

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University
  • Developer Inspyr Therapeutics; National Cancer Institute (USA); University of Texas Health Science Center at Houston
  • Class Antineoplastics; Drug conjugates; Lactones; Peptides; Sesquiterpenes
  • Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Hepatocellular carcinoma; Prostate cancer; Renal cell carcinoma
  • Preclinical Cancer; Gastric cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Aug 2017 Preclinical trials in Cancer (Combination therapy) in USA (unspecified route) (Inspyr Therapeutics pipeline, August 2017)
  • 04 Aug 2017 Preclinical trials in Cancer in USA (unspecified route) (Inspyr Therapeutics pipeline, August 2017)
  • 04 Aug 2017 Inspyr Therapeutics plans a clinical trial for Hepatocellular carcinoma(Monotherapy) in second half of 2017 (Inspyr Therapeutics pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top